PMID- 11981314
OWN - NLM
STAT- MEDLINE
DCOM- 20020912
LR  - 20220410
IS  - 1040-8711 (Print)
IS  - 1040-8711 (Linking)
VI  - 14
IP  - 3
DP  - 2002 May
TI  - Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.
PG  - 204-11
AB  - Tumor necrosis factor-alpha (TNF-alpha) antagonists have rapidly emerged as a 
      valuable class of antirheumatic agents. Etanercept, a dimerized version of the 
      soluble tumor necrosis factor receptor II, and infliximab, a chimeric 
      anti-TNF-alpha monoclonal antibody, are currently approved for the treatment of 
      rheumatoid arthritis (RA) based on their proven beneficial effects in clinical 
      trials. New insights into the role of TNF-alpha in disease pathogenesis have 
      expanded our understanding about the possible mechanisms by which these agents 
      reduce synovial inflammation and inhibit bone and cartilage degradation. The 
      enlarging safety experience has revealed growing concerns about TNF-alpha 
      inhibition and increased risk for opportunistic infection, most notably the 
      reactivation of latent Mycobacterium tuberculosis infection. Recent 
      recommendations have addressed this risk by calling for pretreatment screening 
      for previous exposure to tuberculosis. The success of etanercept and infliximab 
      therapy for RA has prompted the development of other TNF-alpha antagonists and 
      extended the investigation of this therapeutic approach to other inflammatory 
      diseases. TNF-alpha antagonists promise to shape the care of RA and other 
      rheumatic diseases for many years to come.
FAU - Criscione, Lisa G
AU  - Criscione LG
AD  - Division of Rheumatology, Allergy, and Clinical Immunology, Department of 
      Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
FAU - St Clair, E William
AU  - St Clair EW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Mycobacterium tuberculosis
MH  - Rheumatic Diseases/*drug therapy
MH  - Safety
MH  - Tuberculosis/chemically induced
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/metabolism
RF  - 77
EDAT- 2002/05/01 10:00
MHDA- 2002/09/13 10:01
CRDT- 2002/05/01 10:00
PHST- 2002/05/01 10:00 [pubmed]
PHST- 2002/09/13 10:01 [medline]
PHST- 2002/05/01 10:00 [entrez]
AID - 10.1097/00002281-200205000-00002 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2002 May;14(3):204-11. doi: 
      10.1097/00002281-200205000-00002.